Therapy of late chronic phase myelogenous leukemia (CML) with high-dose Gleevec (ST1571)
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 25 Sep 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 25 Sep 2013 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center record.
- 01 Mar 2013 Planned End Date changed from 1 Jul 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov record.